Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation with Cadonilimab and Bevacizumab in HCC with Pulmonary Metastases
NCT06265350Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 months. Started Feb 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06265350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265350.